The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer

被引:39
作者
Tjalma, W
Weyler, J
Weyn, B
Van Marck, E
Van Daele, A
Van Dam, P
Goovaerts, G
Buytaert, P
机构
[1] Univ Antwerp Hosp, Div Gynaecol Oncol, B-2650 Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Pathol, B-2650 Antwerp, Belgium
[3] Univ Antwerp Hosp, Dept Obstet & Gynaecol, B-2650 Antwerp, Belgium
[4] Univ Antwerp, Lab Canc Res & Clin Oncol, B-2610 Antwerp, Belgium
[5] Univ Antwerp, Dept Epidemiol & Community Med, B-2610 Antwerp, Belgium
来源
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 2000年 / 92卷 / 02期
关键词
VEGF; CD; 31; angiogenesis; invasive cervical cancer; prognosis;
D O I
10.1016/S0301-2115(99)00295-X
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The aim of this study was to analyse the vascular endothelial growth factor (VEGF) expression in a series of cervical carcinomas and to compare the results with the microvessel density (MVD) and clinicapathological features. Study design: The immunoreactivity for VEGF was studied in 130 invasive cervical carcinomas and in 22 patients with a carcinoma in situ of the cervix. The results were compared with the MVD. Results: Staining for VEGF of less then 50% per slide occurred in 80% of the invasive carcinomas and in 82% of the in situ carcinomas. The median MVD was 261 vv/mm(2) (range: 11-1000) in the invasive group and 146 vv/mm(2) (range: 25-536) in the in situ group, Unlike the microvessel density there was no association between VEGF expression and survival. The MVD was higher in VEGF poorer (<50%) tumours (P = 0,055). Beside tumour histology (P = 0.012) there were no other significant relationships between the remaining histopathological findings and VEGF expression. Conclusion: Tissue VEGF expression has:no prognostic value in contrast with the MVD in patients with invasive cervical cancer. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:251 / 257
页数:7
相关论文
共 42 条
[1]  
AbuJawdeh GM, 1996, LAB INVEST, V74, P1105
[2]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].
BROWN, LF ;
BERSE, B ;
JACKMAN, RW ;
TOGNAZZI, K ;
GUIDI, AJ ;
DVORAK, HF ;
SENGER, DR ;
CONNOLLY, JL ;
SCHNITT, SJ .
HUMAN PATHOLOGY, 1995, 26 (01) :86-91
[3]   VASCULAR-PERMEABILITY FACTOR MESSENGER-RNA AND PROTEIN EXPRESSION IN HUMAN KIDNEY [J].
BROWN, LF ;
BERSE, B ;
TOGNAZZI, K ;
MANSEAU, EJ ;
VANDEWATER, L ;
SENGER, DR ;
DVORAK, HF ;
ROSEN, S .
KIDNEY INTERNATIONAL, 1992, 42 (06) :1457-1461
[4]  
Claffey KP, 1996, CANCER RES, V56, P172
[5]  
Crew JP, 1997, CANCER RES, V57, P5281
[6]   Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients [J].
Dirix, LY ;
Vermeulen, PB ;
Pawinski, A ;
Prove, A ;
Benoy, I ;
DePooter, C ;
Martin, M ;
VanOosterom, AT .
BRITISH JOURNAL OF CANCER, 1997, 76 (02) :238-243
[7]   EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR DOES NOT PROMOTE TRANSFORMATION BUT CONFERS A GROWTH ADVANTAGE INVIVO TO CHINESE-HAMSTER OVARY CELLS [J].
FERRARA, N ;
WINER, J ;
BURTON, T ;
ROWLAND, A ;
SIEGEL, M ;
PHILLIPS, HS ;
TERRELL, T ;
KELLER, GA ;
LEVINSON, AD .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :160-170
[8]   THE IMPLICATIONS OF ANGIOGENESIS FOR THE BIOLOGY AND THERAPY OF CANCER METASTASIS [J].
FIDLER, IJ ;
ELLIS, LM .
CELL, 1994, 79 (02) :185-188
[9]   ANGIOGENIC FACTORS [J].
FOLKMAN, J ;
KLAGSBRUN, M .
SCIENCE, 1987, 235 (4787) :442-447
[10]  
FOLKMAN J, 1992, J BIOL CHEM, V267, P10931